Generalized Seizures – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Generalized Seizures – Drugs In Development, 2024 report and make more profitable business decisions.
Generalized seizures, are a type of seizure that impairs consciousness and distorts the electrical activity of the whole or a larger portion of the brain. It occurs when the abnormal electrical activity causing a seizure begins in both halves (hemispheres) of the brain at the same time. Generalized seizures occur in various seizure syndromes, including myoclonic epilepsy, familial neonatal convulsions, childhood absence epilepsy, absence epilepsy, infantile spasms (West’s syndrome), Juvenile Myoclonic Epilepsy, Lennox-Gastaut syndrome and Generalized epilepsy with occipital semiology. Generalized seizures can be either absence seizures, myoclonic seizures, clonic seizures, tonic-clonic seizures or atonic seizures.
The Generalized Seizures drugs in development market research report provide comprehensive information on the therapeutics under development for Generalized Seizures, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Generalized Seizures and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Generalized Seizures | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 18 molecules, with 16 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Generalized Seizures therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Generalized Seizures pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Generalized Seizures treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
ANLBio Co LtdAutifony Therapeutics Ltd
Azurity Pharmaceuticals Inc
Center for Biomedical Research for Neurodegenetive Diseases
CuroNZ Ltd
Ionis Pharmaceuticals Inc
Jazz Pharmaceuticals Plc
JC Pharma Inc
Metys Pharmaceuticals AG
Ono Pharmaceutical Co Ltd
Shanghai Institute of Materia Medica Chinese Academy of Sciences
SK Life Science Inc
Taysha Gene Therapies Inc
UCB SA
Valerion Therapeutics LLC (Inactive)
Xenon Pharmaceuticals Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Generalized Seizures reports